Voyager Therapeutics (VYGR) Net Income towards Common Stockholders (2014 - 2026)

Voyager Therapeutics has reported Net Income towards Common Stockholders for 13 years, with the latest figure at -$27.9 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 9.94% year-over-year to -$27.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$116.6 million (down 37.72% YoY) and the FY2025 annual result came in at -$119.7 million, down 84.18% from the prior year.
• Net Income towards Common Stockholders fell to -$27.9 million in Q1 2026 per VYGR's latest filing, from -$27.4 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $124.0 million in Q1 2023 and troughed at -$34.5 million in Q4 2024.
• A 5-year average of -$7.5 million and a median of -$22.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders sank 513.84% in 2022, then surged 681.85% in 2023.
• Over 5 years, Net Income towards Common Stockholders stood at -$23.6 million in 2022, then surged by 338.7% to $56.4 million in 2023, then tumbled by 161.15% to -$34.5 million in 2024, then climbed by 20.47% to -$27.4 million in 2025, then fell by 1.86% to -$27.9 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$27.9 million, -$27.4 million, and -$27.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.